Publicacions científiques

Takao N, Yagishita N, Araya N, Aratani S, Yamauchi J, Takahashi K, Kunitomo Y, Sato T, Nakamori M, Kawai Y, Omae Y, Tokunaga K, Matsuda F, Mitsuhashi S, Yamano Y.

Clinical/Scientific Notes

Any publicació:

2024

Número de revista:

Neurology® Genetics. vol. 10 n. 1

https://www.neurology.org/doi/full/10.1212/NXG.0000000000200108

Late-Onset Ataxia-Telangiectasia Presenting With Dystonia and Tremor

Autor/s:

Jin B, Yoon JG, Kim A, Moon J, Kim HJ

Clinical/Scientific Notes

Any publicació:

2024

Número de revista:

Neurology® Education vol. 3 n. 1

https://www.neurology.org/doi/full/10.1212/NE9.0000000000200113#body-ref-R1

Article

Lateropulsion resolution and outcomes up to one year post-stroke: a prospective, longitudinal cohort study.

Autor/s:

Nolan J, Jacques A, Godecke E, Bynevelt M, Dharsono F, Singer B.

Any publicació:

2024

Número de revista:

Topics in Stroke Rehabilitation vol. 31 n. 8

https://www.tandfonline.com/doi/full/10.1080/10749357.2024.2333186

Learning From the Exception and Not the Rule: Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.

Autor/s:

Fournier CN.

Editorial

Any publicació:

2024

Número de revista:

Neurology vol. 103 n. 4

https://www.neurology.org/doi/full/10.1212/WNL.0000000000209780

Lecanemab for Alzheimer Disease: Is It Worth It?

Autor/s:

Nelson SE, Lopez OL.

Editorial

Any publicació:

2024

Número de revista:

Neurology vol. 102 n. 7

https://www.neurology.org/doi/full/10.1212/WNL.0000000000208072

Article

Lecanemab Planning: Blueprint for Safe and Effective Management of Complex Therapies.

Autor/s:

Shane R, Kremen S, Tan ZS, Tran H, Tu TG, Sicotte NL.

Innovations in Neurologic Practice

Any publicació:

2024

Número de revista:

Neurology® Clinical Practice vol. 14 n. 6

https://www.neurology.org/doi/full/10.1212/CPJ.0000000000200361

Lecanemab Questions.

Autor/s:

Nadeau SE.

Viewpoint

Any publicació:

2024

Número de revista:

Neurology vol. 102 n. 7

https://www.neurology.org/doi/full/10.1212/WNL.0000000000208072

Una iniciativa de:

Cercador

Labor Market Participation of Persons With Spinal Cord Injury Living in Switzerland Between 2012 and 2022: A Comparison to the General Population.

Lactobacillus casei Shirota probiotic drinks reduce antibiotic associated diarrhoea in patients with spinal cord injuries who regularly consume proton pump inhibitors: a subgroup analysis of the ECLISP multicentre RCT.

Lance-Adams Syndrome: It Really Comes From the Cortex!

Large-Scale Whole-Genome Analysis of HTLV-1–Associated Myelopathy Identified Hereditary Spastic Paraplegias

Late-Onset Ataxia-Telangiectasia Presenting With Dystonia and Tremor

Lateropulsion resolution and outcomes up to one year post-stroke: a prospective, longitudinal cohort study.

Learning From the Exception and Not the Rule: Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.

Lecanemab for Alzheimer Disease: Is It Worth It?

Lecanemab Planning: Blueprint for Safe and Effective Management of Complex Therapies.

Lecanemab Questions.

Trobes a faltar informació? Fes-nos arribar els teus suggeriments!